Christopher Madden, MD, Aaron D. Campbell, MD, MHS, and Jessica Pierce, PhD
The use of medication for the prevention and treatment of life-threatening altitude-related illness is very different, medically and morally, from the use of medication to enhance performance.
Harm occurs when race is used as a proxy for characteristics stereotypically ascribed to members of a group, much as the obligatory mention of age is used to indicate the typical patient’s expected health status and vitality.
Medical education must acknowledge the problematic use of race as a biological or epidemiological risk factor in research and the controversy over race.
AMA J Ethics. 2017;19(6):518-527. doi:
10.1001/journalofethics.2017.19.6.peer1-1706.
Viewing dementia as a distinct disease promotes funding for research but may stigmatize those who have dementia and lead to disinvestment in caregiving.
AMA J Ethics. 2017;19(7):713-719. doi:
10.1001/journalofethics.2017.19.7.mhst1-1707.
When deciding whether to offer deep brain stimulation earlier than usual for Parkinson disease, it is important to consider not only the patient’s autonomy but also the validity of the evidence and concepts of harm that are being used to form practice policies.
LaPrincess C. Brewer, MD, MPH and Lisa A. Cooper, MD, MPH
Stressful life experience associated with racial and ethnic discrimination can have detrimental effects on the coronary and cardiovascular health of people in historically marginalized groups.
When identifying underrepresented subgroups deserving of special recruitment efforts for research participation, social determinants of health other than race should be given more consideration.